{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:23:09Z","timestamp":1788805389051,"version":"build-2803163510"},"reference-count":109,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>The global prevalence of obesity has more than tripled since 1975, now affecting nearly one billion adults and over 170 million children and adolescents. In 2025, The Lancet Diabetes &amp; Endocrinology Commission on Clinical Obesity redefined obesity as a chronic, multisystem disease characterised by excess adiposity leading to organ dysfunction, distinguishing between preclinical obesity (excess adiposity without end-organ injury) and clinical obesity (manifest metabolic or structural complications). This framework moves beyond reliance on BMI, acknowledging that ectopic fat deposition in the liver, muscle and viscera is a more accurate determinant of cardiometabolic and hepatic risk. Once considered a disease of affluence, obesity is now increasing most rapidly in rural and low- to middle-income countries, driven by urbanisation of lifestyle, reduced physical activity and the proliferation of ultra-processed foods. The result is a parallel escalation in non-communicable diseases, with obesity underpinning cardiovascular, metabolic, hepatic, renal, respiratory, oncological and psychological disorders, among others. Cardiovascular disease remains the leading cause of obesity-related mortality, while type 2 diabetes, metabolic dysfunction-associated steatotic liver disease and chronic kidney disease contribute substantially to morbidity. Economically, obesity accounted for 2.2% of global GDP in 2019 and is projected to exceed 3% by 2060. Emerging therapies, particularly glucagon-like peptide-1 (GLP-1) and dual GLP-1\/glucose-dependent insulinotropic peptide receptor agonists, now achieve weight loss comparable to metabolic bariatric surgery while reducing cardiovascular, metabolic and hepatic complications, independent of weight loss. Future strategies must integrate precision medicine with equitable, scalable public health policies to address this escalating global epidemic and its societal costs.<\/jats:p>","DOI":"10.15420\/ecr.2025.84","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:08:32Z","timestamp":1779448112000},"source":"Crossref","is-referenced-by-count":2,"title":["The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-9470","authenticated-orcid":false,"given":"Alex E","family":"Henney","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xs57h96","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John PH","family":"Wilding","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xs57h96","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref0","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i\u2013xii. PMID: 11234459."},{"key":"ref1","unstructured":"Ng M, Gakidou E, Lo J, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1; PMID: 40049186."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol 2021;9:419\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(21)00088-7; PMID: 33989535. DOI: 10.1016\/S2213-8587(21)00088-7","DOI":"10.1016\/S2213-8587(21)00088-7"},{"key":"ref3","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4; PMID: 39824205."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 2024;30:2395\u20139. https:\/\/doi.org\/10.1038\/s41591-024-03095-3; PMID: 38969880. DOI: 10.1038\/s41591-024-03095-3","DOI":"10.1038\/s41591-024-03095-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860\u20137. https:\/\/doi.org\/10.1038\/nature05485; PMID: 17167474. DOI: 10.1038\/nature05485","DOI":"10.1038\/nature05485"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:1131\u201341. https:\/\/doi.org\/10.1056\/nejmra1011035; PMID: 25229917. DOI: 10.1056\/NEJMra1011035","DOI":"10.1056\/NEJMra1011035"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85\u201397. https:\/\/doi.org\/10.1038\/nri2921; PMID: 21252989. DOI: 10.1038\/nri2921","DOI":"10.1038\/nri2921"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hall JE, Do Carmo JM, Da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116:991\u20131006. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305697; PMID: 25767285. DOI: 10.1161\/CIRCRESAHA.116.305697","DOI":"10.1161\/CIRCRESAHA.116.305697"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol 2022;29:2218\u201337. https:\/\/doi.org\/10.1093\/eurjpc\/zwac187; PMID: 36007112. DOI: 10.1093\/eurjpc\/zwac187","DOI":"10.1093\/eurjpc\/zwac187"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hildebrand S, Pfeifer A. The obesity pandemic and its impact on non-communicable disease burden. Pflugers Arch 2025;477:657\u201368. https:\/\/doi.org\/10.1007\/s00424-025-03066-8; PMID: 39924587. DOI: 10.1007\/s00424-025-03066-8","DOI":"10.1007\/s00424-025-03066-8"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nagi MA, Ahmed H, Rezq MAA, et al. Economic costs of obesity: a systematic review. Int J Obes (Lond) 2024;48:33\u201343. https:\/\/doi.org\/10.1038\/s41366-023-01398-y; PMID: 37884664. DOI: 10.1038\/s41366-023-01398-y","DOI":"10.1038\/s41366-023-01398-y"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Busebee B, Ghusn W, Cifuentes L, Acosta A. Obesity: a review of pathophysiology and classification. Mayo Clin Proc 2023;98:1842\u201357. https:\/\/doi.org\/10.1016\/j.mayocp.2023.05.026; PMID: 37831039. DOI: 10.1016\/j.mayocp.2023.05.026","DOI":"10.1016\/j.mayocp.2023.05.026"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Peri K, Eisenberg M. Review on obesity management: diet, exercise and pharmacotherapy. BMJ Public Health 2024;2:e000246. https:\/\/doi.org\/10.1136\/bmjph-2023-000246; PMID: 41201084. DOI: 10.1136\/bmjph-2023-000246","DOI":"10.1136\/bmjph-2023-000246"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Idris I, Anyiam O. The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity. Diabetes Obes Metab 2025;27(Suppl 2):20\u201334. https:\/\/doi.org\/10.1111\/dom.16296; PMID: 40026042. DOI: 10.1111\/dom.16296","DOI":"10.1111\/dom.16296"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 2025;406:2257\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(25)01375-3; PMID: 41138739. DOI: 10.1016\/S0140-6736(25)01375-3","DOI":"10.1016\/S0140-6736(25)01375-3"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen TIA. Forecasting the global obesity epidemic through 2050. Lancet 2025;405:756\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(25)00260-0; PMID: 40049184. DOI: 10.1016\/S0140-6736(25)00260-0","DOI":"10.1016\/S0140-6736(25)00260-0"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Islam ANMS, Sultana H, Nazmul Hassan Refat M, et al. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: a meta-analysis. Prev Med Rep 2024;46:102882. https:\/\/doi.org\/10.1016\/j.pmedr.2024.102882; PMID: 39290257. DOI: 10.1016\/j.pmedr.2024.102882","DOI":"10.1016\/j.pmedr.2024.102882"},{"key":"ref18","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature 2019;569:260\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1171-x; PMID: 31068725."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Liu J, Fang Z, Lu Q, et al. Projecting global trends and inequalities in adult overweight and obesity, 2023\u20132040: findings from the NCD-RisC database. Obesity (Silver Spring) 2025;33:1955\u201367. https:\/\/doi.org\/10.1002\/oby.24358; PMID: 40897667. DOI: 10.1002\/oby.24358","DOI":"10.1002\/oby.24358"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ge C, Xiong J, Zhu R, et al. The global burden of high BMI among adolescents between 1990 and 2021. Commun Med (Lond) 2025;5:125. https:\/\/doi.org\/10.1038\/s43856-025-00838-2; PMID: 40247108. DOI: 10.1038\/s43856-025-00838-2","DOI":"10.1038\/s43856-025-00838-2"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Popkin BM, Barquera S, Corvalan C, et al. Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating. Lancet Diabetes Endocrinol 2021;9:462\u201370. https:\/\/doi.org\/10.1016\/S2213-8587(21)00078-4; PMID: 33865500. DOI: 10.1016\/S2213-8587(21)00078-4","DOI":"10.1016\/S2213-8587(21)00078-4"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab 2019;30:67-77.e3. DOI: 10.1016\/j.cmet.2019.05.008","DOI":"10.1016\/j.cmet.2019.05.008"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Passos CMD, Maia EG, Levy RB, et al. Association between the price of ultra-processed foods and obesity in Brazil. Nutr Metab Cardiovasc Dis 2020;30:589\u201398. https:\/\/doi.org\/10.1016\/j.numecd.2019.12.011; PMID: 32139251. DOI: 10.1016\/j.numecd.2019.12.011","DOI":"10.1016\/j.numecd.2019.12.011"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Basto-Abreu A, Torres-Alvarez R, Barrientos-Gutierrez T, et al. Estimated reduction in obesity prevalence and costs of a 20% and 30% ad valorem excise tax to sugar-sweetened beverages in Brazil: a modeling study. PLOS Med 2024;21:e1004399. https:\/\/doi.org\/10.1371\/journal.pmed.1004399; PMID: 39018346. DOI: 10.1371\/journal.pmed.1004399","DOI":"10.1371\/journal.pmed.1004399"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Yao Z, Dardari ZA, Razavi AC, et al. Prevalence of clinical obesity versus BMI-defined obesity among US adults: a cohort study. Lancet Diabetes Endocrinol 2025;13:647\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(25)00159-7; PMID: 41021662. DOI: 10.1016\/S2213-8587(25)00159-7","DOI":"10.1016\/S2213-8587(25)00159-7"},{"key":"ref26","unstructured":"Zahid S, Yao Z, Grimes SN, et al. Epidemiology and natural history of preclinical and clinical obesity: insights from a UK cohort. Obesity (Silver Spring) 2026:NA. https:\/\/doi.org\/10.1002\/oby.70126; PMID: 41559246."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Pearce N, Ebrahim S, McKee M, et al. The road to 25\u00d725: how can the five-target strategy reach its goal? Lancet Glob Health 2014;2:e126\u20138. https:\/\/doi.org\/10.1016\/S2214-109X(14)70015-4; PMID: 25102837. DOI: 10.1016\/S2214-109X(14)70015-4","DOI":"10.1016\/S2214-109X(14)70015-4"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Nilson EAF, Gianicchi B, Ferrari G, Rezende LFM. The projected burden of non-communicable diseases attributable to overweight in Brazil from 2021 to 2030. Sci Rep 2022;12:22483. https:\/\/doi.org\/10.1038\/s41598-022-26739-1; PMID: 36577769. DOI: 10.1038\/s41598-022-26739-1","DOI":"10.1038\/s41598-022-26739-1"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Gallo G, Desideri G, Savoia C. Update on obesity and cardiovascular risk: from pathophysiology to clinical management. Nutrients 2024;16:2781. https:\/\/doi.org\/10.3390\/nu16162781; PMID: 39203917. DOI: 10.3390\/nu16162781","DOI":"10.3390\/nu16162781"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation 2011;124:e837\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.077602; PMID: 22156000. DOI: 10.1161\/CIRCULATIONAHA.111.077602","DOI":"10.1161\/CIRCULATIONAHA.111.077602"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ma L-Z, Sun F-R, Wang Z-T, et al. Metabolically healthy obesity and risk of stroke: a meta-analysis of prospective cohort studies. Ann Transl Med 2021;9:197. https:\/\/doi.org\/10.21037\/atm-20-4387; PMID: 33708824. DOI: 10.21037\/atm-20-4387","DOI":"10.21037\/atm-20-4387"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Bogers RP, Bemelmans WJE, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007;167:1720\u20138. https:\/\/doi.org\/10.1001\/archinte.167.16.1720; PMID: 17846390. DOI: 10.1001\/archinte.167.16.1720","DOI":"10.1001\/archinte.167.16.1720"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Censin JC, Peters SAE, Bovijn J, et al. Causal relationships between obesity and the leading causes of death in women and men. PLOS Genet 2019;15:e1008405. https:\/\/doi.org\/10.1371\/journal.pgen.1008405; PMID: 31647808. DOI: 10.1371\/journal.pgen.1008405","DOI":"10.1371\/journal.pgen.1008405"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218\u201340. https:\/\/doi.org\/10.3390\/nu5041218; PMID: 23584084. DOI: 10.3390\/nu5041218","DOI":"10.3390\/nu5041218"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity \u2013 results of a meta-analysis. Am Heart J 2008;155:310\u20135. https:\/\/doi.org\/10.1016\/j.ahj.2007.10.004; PMID: 18215602. DOI: 10.1016\/j.ahj.2007.10.004","DOI":"10.1016\/j.ahj.2007.10.004"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sha R, Baines O, Hayes A, et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc 2024;13:e032277. https:\/\/doi.org\/10.1161\/JAHA.123.032277; PMID: 38156451. DOI: 10.1161\/JAHA.123.032277","DOI":"10.1161\/JAHA.123.032277"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Moula AI, Parrini I, Tetta C, et al. Obstructive sleep apnea and atrial fibrillation. J Clin Med 2022;11:1242. https:\/\/doi.org\/10.3390\/jcm11051242; PMID: 35268335. DOI: 10.3390\/jcm11051242","DOI":"10.3390\/jcm11051242"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Mar\u00edn-Royo G, Ortega-Hern\u00e1ndez A, Mart\u00ednez-Mart\u00ednez E, et al. The impact of cardiac lipotoxicity on cardiac function and mirnas signature in obese and non-obese rats with myocardial infarction. Sci Rep 2019;9:444. https:\/\/doi.org\/10.1038\/s41598-018-36914-y; PMID: 30679580. DOI: 10.1038\/s41598-018-36914-y","DOI":"10.1038\/s41598-018-36914-y"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Strazzullo P, D\u2019Elia L, Cairella G, et al. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 2010;41:e418\u201326. https:\/\/doi.org\/10.1161\/STROKEAHA.109.576967; PMID: 20299666. DOI: 10.1161\/STROKEAHA.109.576967","DOI":"10.1161\/STROKEAHA.109.576967"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Goldstein LB. Weighing the effect of overweight\/obesity on stroke risk. Stroke 2024;55:1866\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.124.047353; PMID: 38841832. DOI: 10.1161\/STROKEAHA.124.047353","DOI":"10.1161\/STROKEAHA.124.047353"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968\u201376. https:\/\/doi.org\/10.1161\/01.ATV.0000216787.85457.f3; PMID: 16627822. DOI: 10.1161\/01.ATV.0000216787.85457.f3","DOI":"10.1161\/01.ATV.0000216787.85457.f3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Escudero-Mart\u00ednez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: a review and new insights. Trends Cardiovasc Med 2023;33:23\u20139. https:\/\/doi.org\/10.1016\/j.tcm.2021.12.001; PMID: 34890796. DOI: 10.1016\/j.tcm.2021.12.001","DOI":"10.1016\/j.tcm.2021.12.001"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2018.05.018; PMID: 30007554. DOI: 10.1016\/j.jchf.2018.05.018","DOI":"10.1016\/j.jchf.2018.05.018"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol 2013;62:263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092; PMID: 23684677. DOI: 10.1016\/j.jacc.2013.02.092","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2020;320:C375\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020; PMID: 33356944. DOI: 10.1152\/ajpcell.00379.2020","DOI":"10.1152\/ajpcell.00379.2020"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644; PMID: 19805654. DOI: 10.1161\/CIRCULATIONAHA.109.192644","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Verdejo R, Galgani JE. Exploring the sequential accumulation of metabolic syndrome components in adults. Sci Rep 2022;12:15925. https:\/\/doi.org\/10.1038\/s41598-022-19510-z; PMID: 36151232. DOI: 10.1038\/s41598-022-19510-z","DOI":"10.1038\/s41598-022-19510-z"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Marcus Y, Segev E, Shefer G, et al. Metabolically healthy obesity is a misnomer: components of the metabolic syndrome linearly increase with BMI as a function of age and gender. Biology 2023;12:719. https:\/\/doi.org\/10.3390\/biology12050719; PMID: 37237531. DOI: 10.3390\/biology12050719","DOI":"10.3390\/biology12050719"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.034; PMID: 20863953. DOI: 10.1016\/j.jacc.2010.05.034","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 2024;35:697\u2013707. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007; PMID: 38429161. DOI: 10.1016\/j.tem.2024.02.007","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Hsu CL, Loomba R. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research. Nat Metab 2024;6:600\u20132. https:\/\/doi.org\/10.1038\/s42255-024-00985-1; PMID: 38383845. DOI: 10.1038\/s42255-024-00985-1","DOI":"10.1038\/s42255-024-00985-1"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Hydes TJ, Kennedy OJ, Buchanan R, et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK biobank. BMC Med 2023;21:185. https:\/\/doi.org\/10.1186\/s12916-023-02891-x; PMID: 37198624. DOI: 10.1186\/s12916-023-02891-x","DOI":"10.1186\/s12916-023-02891-x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Henney AE, Riley DR, Hydes TJ, et al. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD. Liver Int 2024;44:3031\u201349. https:\/\/doi.org\/10.1111\/liv.16086; PMID: 39221811. DOI: 10.1111\/liv.16086","DOI":"10.1111\/liv.16086"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Cuthbertson DJ, Kennedy OJ, Bilson J, et al. Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes. Metabolism 2025;170:156306. https:\/\/doi.org\/10.1016\/j.metabol.2025.156306; PMID: 40414560. DOI: 10.1016\/j.metabol.2025.156306","DOI":"10.1016\/j.metabol.2025.156306"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 2018;8:15273. https:\/\/doi.org\/10.1038\/s41598-018-33419-6; PMID: 30323178. DOI: 10.1038\/s41598-018-33419-6","DOI":"10.1038\/s41598-018-33419-6"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis 2024;23:117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x; PMID: 38649999. DOI: 10.1186\/s12944-024-02108-x","DOI":"10.1186\/s12944-024-02108-x"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lu C-W, Chou T-J, Wu T-Y, et al. PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population. Ann Hepatol 2025;30:101761. https:\/\/doi.org\/10.1016\/j.aohep.2024.101761; PMID: 39638042. DOI: 10.1016\/j.aohep.2024.101761","DOI":"10.1016\/j.aohep.2024.101761"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Deng M, Li Z, Sun L, et al. Liver MRI-derived proton density fat fraction predicts diabetes risk in patients with obesity: a dose-response study. Radiology 2025;317:e250026. https:\/\/doi.org\/10.1148\/radiol.250026; PMID: 41117648. DOI: 10.1148\/radiol.250026","DOI":"10.1148\/radiol.250026"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus \u2013 an overview. Int J Mol Sci 2024;25:1882. https:\/\/doi.org\/10.3390\/ijms25031882; PMID: 38339160. DOI: 10.3390\/ijms25031882","DOI":"10.3390\/ijms25031882"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, De Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021; PMID: 31279902. DOI: 10.1016\/j.jhep.2019.06.021","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Klein S, Gastaldelli A, Yki-J\u00e4rvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab 2022;34:11\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2021.12.012; PMID: 34986330. DOI: 10.1016\/j.cmet.2021.12.012","DOI":"10.1016\/j.cmet.2021.12.012"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Deng L, Jia L, Wu XL, Cheng M. Association between body mass index and glycemic control in type 2 diabetes mellitus: a cross-sectional study. Diabetes Metab Syndr Obes 2025;18:555\u201363. https:\/\/doi.org\/10.2147\/DMSO.S508365; PMID: 40007519. DOI: 10.2147\/DMSO.S508365","DOI":"10.2147\/DMSO.S508365"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Gray N, Picone G, Sloan F, Yashkin A. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J 2015;108:29\u201336. https:\/\/doi.org\/10.14423\/SMJ.0000000000000214; PMID: 25580754. DOI: 10.14423\/SMJ.0000000000000214","DOI":"10.14423\/SMJ.0000000000000214"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Taylor R, Barnes AC, Hollingsworth KG, et al. Aetiology of type 2 diabetes in people with a \u2018normal\u2019 body mass index: testing the personal fat threshold hypothesis. Clin Sci (Lond) 2023;137:1333\u201346. https:\/\/doi.org\/10.1042\/CS20230586; PMID: 37593846. DOI: 10.1042\/CS20230586","DOI":"10.1042\/CS20230586"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048\u201350. https:\/\/doi.org\/10.1016\/j.kint.2019.07.012; PMID: 31582227. DOI: 10.1016\/j.kint.2019.07.012","DOI":"10.1016\/j.kint.2019.07.012"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Carro C, Vergara A, Bermejo S, et al. A nephrologist perspective on obesity: from kidney injury to clinical management. Front Med (Lausanne) 2021;8:655871. https:\/\/doi.org\/10.3389\/fmed.2021.655871; PMID: 33928108. DOI: 10.3389\/fmed.2021.655871","DOI":"10.3389\/fmed.2021.655871"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 2019;364:k5301. https:\/\/doi.org\/10.1136\/bmj.k5301; PMID: 30630856. DOI: 10.1136\/bmj.k5301","DOI":"10.1136\/bmj.k5301"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Sun M, Da Silva M, Bj\u00f8rge T, et al. Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: the Obesity and Disease Development Sweden (ODDS) pooled cohort study. Lancet Reg Health Eur 2024;45:101034. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101034; PMID: 39253735. DOI: 10.1016\/j.lanepe.2024.101034","DOI":"10.1016\/j.lanepe.2024.101034"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol 2020;8:616\u201327. https:\/\/doi.org\/10.1016\/S2213-8587(20)30110-8; PMID: 32559477. DOI: 10.1016\/S2213-8587(20)30110-8","DOI":"10.1016\/S2213-8587(20)30110-8"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Chen S, Zhang H, Gao M, et al. Dose-dependent association between body mass index and mental health and changes over time. JAMA Psychiatry 2024;81:797\u2013806. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0921; PMID: 38748415. DOI: 10.1001\/jamapsychiatry.2024.0921","DOI":"10.1001\/jamapsychiatry.2024.0921"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Qiao Z, Wang Z, Qiu J, et al. Analysis of the effect of BMI on depression and anxiety among older adults in China: the mediating role of ADL and IADL. Front Public Health 2024;12:1387550. https:\/\/doi.org\/10.3389\/fpubh.2024.1387550; PMID: 39296846. DOI: 10.3389\/fpubh.2024.1387550","DOI":"10.3389\/fpubh.2024.1387550"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Fu X, Wang Y, Zhao F, et al. Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines. Aging (Albany, NY) 2023;15:5917\u201350. https:\/\/doi.org\/10.18632\/aging.204847; PMID: 37387537. DOI: 10.18632\/aging.204847","DOI":"10.18632\/aging.204847"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health 2022;7:e009773. https:\/\/doi.org\/10.1136\/bmjgh-2022-009773; PMID: 36130777. DOI: 10.1136\/bmjgh-2022-009773","DOI":"10.1136\/bmjgh-2022-009773"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Bjornson AM, Szabo SM, Donato BMK, et al. Costs of obesity, obesity-related complications, and weight loss in the United States: a systematic literature review. J Manag Care Spec Pharm 2025;31:851\u201361. https:\/\/doi.org\/10.18553\/jmcp.2025.25051; PMID: 40673677. DOI: 10.18553\/jmcp.2025.25051","DOI":"10.18553\/jmcp.2025.25051"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Altunkaya J, Piernas C, Pouwels KB, et al. Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study. Lancet Diabetes Endocrinol 2024;12:462\u201371. https:\/\/doi.org\/10.1016\/S2213-8587(24)00129-3; PMID: 38843849. DOI: 10.1016\/S2213-8587(24)00129-3","DOI":"10.1016\/S2213-8587(24)00129-3"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323\u201341. https:\/\/doi.org\/10.1146\/annurev.nutr.21.1.323. DOI: 10.1146\/annurev.nutr.21.1.323","DOI":"10.1146\/annurev.nutr.21.1.323"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365:1597\u2013604. https:\/\/doi.org\/10.1056\/NEJMoa1105816; PMID: 22029981. DOI: 10.1056\/NEJMoa1105816","DOI":"10.1056\/NEJMoa1105816"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Thorogood A, Mottillo S, Shimony A, et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2011;124:747\u201355. https:\/\/doi.org\/10.1016\/j.amjmed.2011.02.037; PMID: 21787904. DOI: 10.1016\/j.amjmed.2011.02.037","DOI":"10.1016\/j.amjmed.2011.02.037"},{"key":"ref79","unstructured":"National Institute of Health and Care Excellence. Overweight and obesity management. 2025. https:\/\/www.nice.org.uk\/guidance\/NG246\/chapter\/medicines-and-surgery (accessed 5 November 2025)"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Maciejewski ML, Arterburn DE, Van Scoyoc L, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg 2016;151:1046\u201355. https:\/\/doi.org\/10.1001\/jamasurg.2016.2317; PMID: 27579793. DOI: 10.1001\/jamasurg.2016.2317","DOI":"10.1001\/jamasurg.2016.2317"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Carlsson LMS, Sj\u00f6holm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study. N Engl J Med 2020;383:1535\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2002449; PMID: 33053284. DOI: 10.1056\/NEJMoa2002449","DOI":"10.1056\/NEJMoa2002449"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring) 2013;21:1093\u2013103. https:\/\/doi.org\/10.1002\/oby.20364; PMID: 23512841. DOI: 10.1002\/oby.20364","DOI":"10.1002\/oby.20364"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"M\u00fcnzberg H, Laque A, Yu S, et al. Appetite and body weight regulation after bariatric surgery. Obes Rev 2015;16(Suppl 1):77\u201390. https:\/\/doi.org\/10.1111\/obr.12258; PMID: 25614206. DOI: 10.1111\/obr.12258","DOI":"10.1111\/obr.12258"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Barrett TS, Hafermann JO, Richards S, et al. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg 2025;160:1232\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2025.3590; PMID: 40960852. DOI: 10.1001\/jamasurg.2025.3590","DOI":"10.1001\/jamasurg.2025.3590"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038; PMID: 35658024. DOI: 10.1056\/NEJMoa2206038","DOI":"10.1056\/NEJMoa2206038"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, et al. Efficacy and Safety of semaglutide 7.2 mg in Obesity \u2014 STEP UP trial. Diabetes 2025;74(Suppl 1):1966-LB. https:\/\/doi.org\/10.2337\/db25-1966-LB. DOI: 10.2337\/db25-1966-LB","DOI":"10.2337\/db25-1966-LB"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183; PMID: 33567185. DOI: 10.1056\/NEJMoa2032183","DOI":"10.1056\/NEJMoa2032183"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892; PMID: 26132939. DOI: 10.1056\/NEJMoa1411892","DOI":"10.1056\/NEJMoa1411892"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 a Phase 2 trial. N Engl J Med 2023;389:514\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2301972; PMID: 37366315. DOI: 10.1056\/NEJMoa2301972","DOI":"10.1056\/NEJMoa2301972"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025;393:635\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2502081; PMID: 40544433. DOI: 10.1056\/NEJMoa2502081","DOI":"10.1056\/NEJMoa2502081"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID: 37952131. DOI: 10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027; PMID: 39555826. DOI: 10.1056\/NEJMoa2410027","DOI":"10.1056\/NEJMoa2410027"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Zhang H-D, Ding L, Liu K, et al. Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis. Diabetes Metab Syndr 2024;18:103067. https:\/\/doi.org\/10.1016\/j.dsx.2024.103067; PMID: 38955095. DOI: 10.1016\/j.dsx.2024.103067","DOI":"10.1016\/j.dsx.2024.103067"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Wu J-Y, Tseng K-J, Kao C-L, et al. Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract 2025;225:112279. https:\/\/doi.org\/10.1016\/j.diabres.2025.112279; PMID: 40412626. DOI: 10.1016\/j.diabres.2025.112279","DOI":"10.1016\/j.diabres.2025.112279"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943; PMID: 38856224. DOI: 10.1056\/NEJMoa2401943","DOI":"10.1056\/NEJMoa2401943"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Henney AE, Riley DR, Anson M, et al. Target trial emulations of GLP-1 and dual GLP-1\/GIP agonists to reduce major adverse liver outcomes in type 2 diabetes. Liver Int 2025;45:e70367. https:\/\/doi.org\/10.1111\/liv.70367; PMID: 40980971. DOI: 10.1111\/liv.70367","DOI":"10.1111\/liv.70367"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Jessen N, St\u00f8vring H. Cancer risk with GLP-1RA: what can real-world data really tell us? Lancet Reg Health Eur 2025;55:101383. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101383; PMID: 40704041. DOI: 10.1016\/j.lanepe.2025.101383","DOI":"10.1016\/j.lanepe.2025.101383"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Wang W, Davis PB, Qi X, et al. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis 2025;106:1509\u201322. https:\/\/doi.org\/10.1177\/13872877251351329; PMID: 40552638. DOI: 10.1177\/13872877251351329","DOI":"10.1177\/13872877251351329"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Henney AE, Riley DR, Hydes TJ, et al. Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax 2024;80:32\u201341. https:\/\/doi.org\/10.1136\/thorax-2024-221906; PMID: 39645259. DOI: 10.1136\/thorax-2024-221906","DOI":"10.1136\/thorax-2024-221906"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Henney AE, Riley DR, Heague M, et al. Relative efficacy of GLP-1 and GLP-1\/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. Diabetes Obes Metab 2025;28:137\u201350. https:\/\/doi.org\/10.1111\/dom.70169; PMID: 41058240. DOI: 10.1111\/dom.70169","DOI":"10.1111\/dom.70169"},{"key":"ref101","unstructured":"World Health Organization. WHO Acceleration Plan to Stop Obesity. 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240075634 (accessed 5 November 2025)"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Saxena A, Koon AD, Johnson Curtis C, et al. Estimated health impact, cost, and cost-effectiveness of taxation on unhealthy packaged foods in the Philippines: a modelling study. Lancet Public Health 2025;10:e824\u201334. https:\/\/doi.org\/10.1016\/S2468-2667(25)00191-4; PMID: 40876471. DOI: 10.1016\/S2468-2667(25)00191-4","DOI":"10.1016\/S2468-2667(25)00191-4"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"McManus E, Meacock R, Parkinson B, Sutton M. Population level impact of the NHS Diabetes Prevention Programme on incidence of type 2 diabetes in England: an observational study. Lancet Reg Health Eur 2022;19:100420. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100420; PMID: 35664052. DOI: 10.1016\/j.lanepe.2022.100420","DOI":"10.1016\/j.lanepe.2022.100420"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Usher-Smith JA, Shah VP, Nahreen S, et al. Evaluation of the reach and impact of a UK campaign highlighting obesity as a cause of cancer among the general public and Members of Parliament. Public Health 2023;219:131\u20138. https:\/\/doi.org\/10.1016\/j.puhe.2023.03.026; PMID: 37167643. DOI: 10.1016\/j.puhe.2023.03.026","DOI":"10.1016\/j.puhe.2023.03.026"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Nadolsky K, Garvey WT, Agarwal M, et al. American Association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease \u2013 2025 update. Endocr Pract 2025;31:1351\u201394. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.017; PMID: 40956256. DOI: 10.1016\/j.eprac.2025.07.017","DOI":"10.1016\/j.eprac.2025.07.017"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Mamas MA, Bays H, Li R, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open 2025;5:oeaf117. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf117; PMID: 40980721. DOI: 10.1093\/ehjopen\/oeaf117","DOI":"10.1093\/ehjopen\/oeaf117"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Teke J, Msiska M, Adanini OA, et al. Artificial intelligence for obesity management: a review of applications, opportunities, and challenges. Obes Med 2025;58:100657. https:\/\/doi.org\/10.1016\/j.obmed.2025.100657. DOI: 10.1016\/j.obmed.2025.100657","DOI":"10.1016\/j.obmed.2025.100657"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Kandi SR, Khera R, Rajagopalan S, Neeland IJ. AI in adipose imaging: revolutionizing visceral adipose tissue, ectopic fat, and cardiovascular risk assessment. Curr Atheroscler Rep 2025;27:101. https:\/\/doi.org\/10.1007\/s11883-025-01356-1; PMID: 41068345. DOI: 10.1007\/s11883-025-01356-1","DOI":"10.1007\/s11883-025-01356-1"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.84","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:06:28Z","timestamp":1779876388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":109,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.84","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"e25"}}